Fundraise / allotmentFiled on BSE ·
Manipal Hospitals redeems ₹5,310 crore NCDs using IPO proceeds in September 2026
Manipal Health Enterprises Ltd
What the filing says
- Redeemed ₹5,310 crore non-convertible debentures (NCDs) fully using IPO proceeds as of September 17, 2026.
- Redemption includes principal, accrued interest, and prepayment costs, strengthening balance sheet and financial leverage.
- Manipal Hospitals operates 50 multispecialty hospitals across 14 states with over 13,000 beds and 11,000 doctors.
Original filing
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Revenue growth 40%+Margin up 2%+
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Manipal Health Enterprises Ltd
- Fundraise / allotmentManipal Health Enterprises redeems ₹5,310 crore debentures using IPO proceeds
Other fundraise / allotment filings this fortnight
- Fundraise / allotmentMangalam Global Enterprise LtdMangalam Global Enterprise Limited approves issuance of NCDs worth up to ₹150 crore
- Fundraise / allotmentMangalam Global Enterprise LtdMangalam Global Enterprise Limited approves issuance of NCDs worth ₹150 crore
- Fundraise / allotmentRegency FincorpRegency Fincorp Limited announces preferential issue and ESOP proposal
- Fundraise / allotmentRegency FincorpRegency Fincorp approves ₹312.15 crore fundraise via equity and warrants
- Fundraise / allotmentRegency FincorpRegency Fincorp receives Board approval for ₹312.15 crore fundraise via equity and warrants
- Fundraise / allotmentSahana Systems LtdSahana System Limited approves preferential issue of warrants and director appointment
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.